NCT06987552 Single-Port RAS Using Da Vinci SP Surgical System for UTUC Patients
| NCT ID | NCT06987552 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Upper Tract Urothelial Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2024-12-24 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 25 participants in total. It began in 2024-12-24 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate patient-reported outcomes of radical nephroureterectomy using single-port robotic surgery
Eligibility Criteria
Inclusion Criteria: * Age 20 years or more * Histologically or cytologically diagnosed upper tract urothelial cancer * Fitting indications of radical nephroureterectomy and ipsilateral bladder cuff resection, and deemed feasible for robotic surgery * ASA physical status classification 1-2 and adequate organ function * Patients willing and able to comply with study protocol requirements and follow-up * With informed consent Exclusion Criteria: * Synchronous bladder cancer * Distant metastasis of cancer * BMI ≥30 or BMI \<18.5 * Unable to tolerate lateral decubitus or Trendelenburg position (relative contra-indication) * Severe adhesion due to prior abdominopelvic surgery (relative contra-indication) * Previous radiation treatment to the pelvic area * Active infectious disease * Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic interventions, such as: severe heart disease (NYHA functional class III-IV) or severe lung disease (GOLD Group C-D) * Cannot follow trial-required procedures * Concomitant systemic or pelvic disease that increases the risk of surgery * Long-term use of anti-coagulant(s) * Patients with coagulopathy * Emergency surgery
Contact & Investigator
Shih-Chieh Chueh
STUDY DIRECTOR
National Taiwan University Hospital
Frequently Asked Questions
Who can join the NCT06987552 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Upper Tract Urothelial Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06987552 currently recruiting?
Yes, NCT06987552 is actively recruiting participants. Contact the research team at jeffchueh@gmail.com for enrollment information.
Where is the NCT06987552 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT06987552 clinical trial?
NCT06987552 is sponsored by National Taiwan University Hospital. The principal investigator is Shih-Chieh Chueh at National Taiwan University Hospital. The trial plans to enroll 25 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.